ReviewFrontiers in oncology2025
The place of advanced machine learning techniques in building pancreatic adenocarcinoma survival and recurrence prognosis models.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Insights into artificial intelligence-based digital pathology in hepatobiliary and pancreatic cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy, and traditional prognostic methods, such as TNM staging, often fail to accurately predict outcomes. This review evaluates the use of machine learning (ML) to improve PDAC prognosis. Methods: A systematic literature search of PubMed and Google Scholar was conducted, identifying 12 studies that applied ML algorithms to predict survival, recurrence, and metastasis in patients with PDAC. Results: Various algorithms, including Random Forests, XGBoost, and Deep Learning, demonstrated superior predictive performance compared to the TNM staging. Models using multimodal data-combining clinical, radiomic, and genomic features-yielded the highest accuracy for predicting overall survival and early liver metastasis. Conclusion: ML offers a significant advantage in analyzing complex medical data to refine risk stratification and support personalized PDAC treatment. However, current models are limited by their small datasets and retrospective designs. Future research requires prospective validation to translate these ML tools into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.